Starling Oncology, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -51.0% | -41.3% | -21.8% |
| FY2021 | -10.5% | -10.5% | -5.4% |
| FY2022 | 0.1% | 0.1% | 0.1% |
| FY2023 | -145.7% | -57.7% | -39.7% |
| FY2024 | -1,801.7% | -66.9% | -37.4% |
| FY2025 | 385.5% | -98.3% | -36.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -51.0% | -41.3% | -21.8% |
| FY2021 | -10.5% | -10.5% | -5.4% |
| FY2022 | 0.1% | 0.1% | 0.1% |
| FY2023 | -145.7% | -57.7% | -39.7% |
| FY2024 | -1,801.7% | -66.9% | -37.4% |
| FY2025 | 385.5% | -98.3% | -36.8% |